{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:12:31Z","timestamp":1790244751895,"version":"4.1.0"},"reference-count":316,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"abstract":"<jats:p>Modern oncologic treatments such as antibody\u2010drug conjugates, targeted therapies, CAR\u2010T\u2010cell therapies and immune checkpoint inhibitors show improved efficacy through novel mechanisms of action when compared to conventional chemotherapy. However, these agents are often associated with cutaneous adverse events, many of them with distinctive clinical and histopathological patterns. Such events may be severe, impairing quality of life and sometimes leading to interruption of critical cancer treatment. As the use of these therapies continues to expand, dermatologists and dermatopathologists will increasingly encounter their associated toxicities. Recognition of histopathological patterns enables an accurate diagnosis and guides clinical management. Herein, we review the main cutaneous adverse events associated with antibody\u2010drug conjugates, targeted therapies, CAR\u2010T cell therapies and immune checkpoint inhibitors, summarizing clinical features and emphasizing histopathological findings.<\/jats:p>","DOI":"10.1111\/his.70286","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:55:26Z","timestamp":1790243726000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cutaneous reactions to modern systemic oncologic therapies: a histopathological and clinical review"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-1260","authenticated-orcid":false,"given":"Elisa Scandiuzzi","family":"Maciel","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3150-1938","authenticated-orcid":false,"given":"Anna E","family":"Kersh","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5625-2782","authenticated-orcid":false,"given":"Emily Y","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Pennsylvania  Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.24406","article-title":"Clinical trial evidence supporting US Food and Drug Administration approval of novel cancer therapies between 2000 and 2016","volume":"3","author":"Ladanie A","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/164_2019_312","article-title":"The evolving landscape of cancer therapeutics","volume":"260","author":"Khan M","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0819-1","article-title":"CAR\u2010T \u201cthe living drugs\u201d, immune checkpoint inhibitors, and precision medicine: A new era of cancer therapy","volume":"12","author":"Liu D","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2021.07.017","article-title":"Cutaneous manifestations of chimeric antigen receptor T\u2010cell therapy: An introduction for dermatologists","volume":"87","author":"Nusbaum KB","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.061"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jaad.2024.08.036","article-title":"Dermatologic toxicities of antibody\u2010drug conjugates","volume":"91","author":"Gronbeck C","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.humpath.2023.04.014","article-title":"Cutaneous adverse reactions resulting from targeted cancer therapies: Histopathologic and clinical findings","volume":"140","author":"Haynes D","year":"2023","journal-title":"Hum. Pathol."},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.humpath.2023.04.016","article-title":"Immune checkpoint inhibitor\u2010induced cutaneous toxicities: A review of histopathologic and clinical features","volume":"140","author":"Martel J","year":"2023","journal-title":"Hum. Pathol."},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-025-03193-3","article-title":"Drug\u2010induced cutaneous toxicities in solid tumor oncology: Mechanisms, manifestations, and management","volume":"43","author":"Skossyrskiy V","year":"2025","journal-title":"Med. Oncol."},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70699","article-title":"Antibody\u2010drug conjugates in oncology: Principles, clinical development, and future directions","volume":"7","author":"Cheng B","year":"2026","journal-title":"MedComm"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu Z","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102943"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_2_12_15_1","first-page":"165","article-title":"Antibody\u2010drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino P","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaad.2024.07.1463","article-title":"Antibody\u2010drug conjugates: A review of cutaneous adverse effects","volume":"91","author":"Saberi SA","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV\u2010302): Patient\u2010reported outcomes from an open\u2010label, randomised, controlled, phase 3 study","volume":"26","author":"Gupta S","year":"2025","journal-title":"Lancet Oncol."},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles T","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD\u20101 or PD\u2010L1 inhibitors in cisplatin\u2010ineligible patients with advanced urothelial carcinoma (EV\u2010201): A multicentre, single\u2010arm, phase 2 trial","volume":"22","author":"Yu EY","year":"2021","journal-title":"Lancet Oncol."},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"595.e1","DOI":"10.1016\/j.urolonc.2025.05.016","article-title":"Enfortumab vedotin\u2010related skin toxicities in patients with urothelial carcinoma: A systematic review and meta\u2010analysis","volume":"43","author":"Gazzoni G","year":"2025","journal-title":"Urol. Oncol."},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles T","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"e_1_2_12_22_1","article-title":"Toxicity profile of enfortumab vedotin with or without pembrolizumab in patients with metastatic urothelial carcinoma: A systematic review and meta\u2010analysis","volume":"43","author":"Aleixo Sim\u00f5es C","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.21873\/anticanres.17115","article-title":"Cutaneous and renal toxicities of Enfortumab Vedotin for advanced urothelial carcinoma: The UROKYU study","volume":"44","author":"Furubayashi N","year":"2024","journal-title":"Anticancer Res."},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab Vedotin with or without Pembrolizumab in cisplatin\u2010ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell PH","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of Dermatologic Events Associated with the Nectin\u20104\u2010directed antibody\u2010drug conjugate Enfortumab Vedotin","volume":"27","author":"Lacouture ME","year":"2022","journal-title":"Oncologist"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.801199","article-title":"Cutaneous toxicity associated with Enfortumab Vedotin: A real\u2010word study leveraging U.S. Food and Drug Administration adverse event reporting system","volume":"11","author":"Yang H","year":"2021","journal-title":"Front. Oncol."},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/ijd.70258","article-title":"Clinicopathologic and Immunohistochemical features of Enfortumab Vedotin\u2010induced cutaneous toxicity","volume":"65","author":"Repetto F","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/1346-8138.17901","article-title":"Enfortumab Vedotin\u2010related skin toxicities: Insights from clinical and histopathological analysis","volume":"52","author":"Kuma Y","year":"2025","journal-title":"J. Dermatol."},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/cup.14689","article-title":"Enfortumab vedotin\u2010induced cutaneous eruption: Ring mitotic figures as a distinctive histopathologic feature","volume":"51","author":"Sport C","year":"2024","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.621591","article-title":"Case report: Enfortumab Vedotin for metastatic urothelial carcinoma: A case series on the clinical and histopathologic Spectrum of adverse cutaneous reactions from fatal Stevens\u2010Johnson syndrome\/toxic epidermal necrolysis to dermal hypersensitivity reaction","volume":"11","author":"Viscuse PV","year":"2021","journal-title":"Front. Oncol."},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/DAD.0000000000003004","article-title":"Two cases of cutaneous adverse events induced by Enfortumab Vedotin with Ring mitosis: A characteristic but rare histologic finding","volume":"47","author":"Aitake U","year":"2025","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/DAD.0000000000002911","article-title":"Histopathologic comparison among drug eruptions induced by Enfortumab Vedotin, Brentuximab Vedotin, and Taxanes","volume":"47","author":"Iwahashi Y","year":"2025","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/bjd.21022","article-title":"Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin","volume":"187","author":"Penny CL","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2010drug conjugates for cancer therapy","volume":"17","author":"Thomas A","year":"2016","journal-title":"Lancet Oncol."},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30\u2010positive cutaneous T\u2010cell lymphoma (ALCANZA): An international, open\u2010label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince HM","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"e_1_2_12_36_1","article-title":"Dermatologic adverse events of brentuximab vedotin: Characteristics, management, and their relationship with dose regimen","volume":"39","author":"Oh Y","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/phar.1170","article-title":"Brentuximab vedotin: A CD30\u2010directed antibody\u2010cytotoxic drug conjugate","volume":"33","author":"Newland AM","year":"2013","journal-title":"Pharmacotherapy"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1097\/PAS.0000000000002268","article-title":"Histopathologic and clinical characterization of Brentuximab Vedotin\u2010associated rash","volume":"48","author":"Narala S","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.det.2026.01.009","article-title":"New and emerging drug reactions","volume":"44","author":"Chu EY","year":"2026","journal-title":"Dermatol. Clin."},{"issue":"1","key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, Oral mucosa, hair, and nails","volume":"19","author":"Lacouture M","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/ijd.12205","article-title":"Dermatologic toxicities to targeted cancer therapy: Shared clinical and histologic adverse skin reactions","volume":"53","author":"Curry JL","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"e_1_2_12_42_1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI128678","article-title":"IL\u201036gamma drives skin toxicity induced by EGFR\/MEK inhibition and commensal Cutibacterium acnes","volume":"130","author":"Satoh TK","year":"2020","journal-title":"J. Clin. Invest."},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel SA","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel RS","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: Focus on kinase inhibitors","volume":"66","author":"Li W","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0923-1811(00)00145-6","article-title":"The role of VEGF and thrombospondins in skin angiogenesis","volume":"24","author":"Detmar M","year":"2000","journal-title":"J. Dermatol. Sci."},{"key":"e_1_2_12_47_1","first-page":"1827","article-title":"Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: A meta\u2010analysis and review of the literature","volume":"23","author":"Massey PR","year":"2015","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jaad.2019.04.021","article-title":"Risk of hand\u2010foot skin reaction associated with vascular endothelial growth factor\u2010tyrosine kinase inhibitors: A meta\u2010analysis of 57 randomized controlled trials involving 24,956 patients","volume":"83","author":"Ding F","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_49_1","article-title":"Clinical characteristics, treatment outcomes, and prognosis in patients with MKIs\u2010associated hand\u2010foot skin reaction: A retrospective study","volume":"31","author":"Shou L","year":"2023","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_50_1","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/annonc\/mdv244","article-title":"Regorafenib\u2010associated hand\u2010foot skin reaction: Practical advice on diagnosis, prevention, and management","volume":"26","author":"McLellan B","year":"2015","journal-title":"Ann. Oncol."},{"key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier J","year":"2008","journal-title":"Arch. Dermatol."},{"key":"e_1_2_12_52_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jamadermatol.2014.2734","article-title":"Cutaneous adverse effects associated with the tyrosine\u2010kinase inhibitor cabozantinib","volume":"151","author":"Zuo RC","year":"2015","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_53_1","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/pde.15967","article-title":"Regorafenib\u2010induced hand\u2010foot skin reaction in an adolescent","volume":"42","author":"Murphy K","year":"2025","journal-title":"Pediatr. Dermatol."},{"key":"e_1_2_12_54_1","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1610-0387.2010.07449.x","article-title":"The hand\u2010foot\u2010syndrome associated with medical tumor therapy \u2010 classification and management","volume":"8","author":"Degen A","year":"2010","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"e_1_2_12_55_1","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1001\/archdermatol.2011.320","article-title":"Capecitabine\u2010induced hand\u2010foot syndrome complicated by pseudomonal superinfection resulting in bacterial sepsis and death: Case report and review of the literature","volume":"147","author":"Hoesly FJ","year":"2011","journal-title":"Arch. Dermatol."},{"key":"e_1_2_12_56_1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2011.05057.x","article-title":"Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib","volume":"51","author":"Iacovelli R","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"e_1_2_12_57_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.5414\/CP204697","article-title":"Severe genital cutaneous toxicity with sunitinib","volume":"63","author":"Rodriguez Jorge M","year":"2025","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"e_1_2_12_58_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","article-title":"Skin tumors induced by sorafenib; paradoxic RAS\u2010RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1","volume":"18","author":"Arnault JP","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_12_59_1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaad.2009.04.026","article-title":"Lymphatic invasion detected by D2\u201040\/S\u2010100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma","volume":"61","author":"Petitt M","year":"2009","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_60_1","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/j.1524-4725.2009.01289.x","article-title":"Eruptive keratoacanthoma\u2010type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors","volume":"35","author":"Smith KJ","year":"2009","journal-title":"Dermatologic Surg."},{"key":"e_1_2_12_61_1","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.18632\/oncotarget.28046","article-title":"The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: A case series","volume":"12","author":"Drenner K","year":"2021","journal-title":"Oncotarget"},{"key":"e_1_2_12_62_1","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(14)71133-7","article-title":"Nail toxicities induced by systemic anticancer treatments","volume":"16","author":"Robert C","year":"2015","journal-title":"Lancet Oncol."},{"issue":"6","key":"e_1_2_12_63_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/jdv.18200","article-title":"Anticancer treatments and photosensitivity","volume":"36","author":"Sibaud V","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_2_12_64_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","article-title":"Sunitinib: A multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies","volume":"23","author":"Papaetis GS","year":"2009","journal-title":"BioDrugs"},{"key":"e_1_2_12_65_1","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/j.clgc.2016.12.018","article-title":"Risk of distinctive hair changes associated with Pazopanib in patients with renal cell carcinoma (RCC) versus patients without RCC: A comparative systematic review and meta\u2010analysis","volume":"15","author":"Elhalawani H","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"e_1_2_12_66_1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture ME","year":"2008","journal-title":"Ann. Oncol."},{"key":"e_1_2_12_67_1","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","article-title":"Hand\u2010foot skin reaction in patients treated with sorafenib: A clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy","volume":"158","author":"Yang CH","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_68_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side\u2010effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert C","year":"2005","journal-title":"Lancet Oncol."},{"key":"e_1_2_12_69_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy\u2010induced palmar plantar erythrodysesthesia ('hand\u2010foot') syndrome. Incidence, recognition and management","volume":"1","author":"Nagore E","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"key":"e_1_2_12_70_1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMc0802736","article-title":"Scrotal cutaneous side effects of sunitinib","volume":"359","author":"Billemont B","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_71_1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1152\/physrev.00030.2015","article-title":"Expression and function of the epidermal growth factor receptor in physiology and disease","volume":"96","author":"Chen J","year":"2016","journal-title":"Physiol. Rev."},{"key":"e_1_2_12_72_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2353\/ajpath.2008.070942","article-title":"Beyond wavy hairs: The epidermal growth factor receptor and its ligands in skin biology and pathology","volume":"173","author":"Schneider MR","year":"2008","journal-title":"Am. J. Pathol."},{"key":"e_1_2_12_73_1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello F","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_74_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","article-title":"Epidermal growth factor receptor inhibitors in cancer treatment: Advances, challenges and opportunities","volume":"20","author":"Modjtahedi H","year":"2009","journal-title":"Anti\u2010Cancer Drugs"},{"key":"e_1_2_12_75_1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamadermatol.2020.1795","article-title":"Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center","volume":"156","author":"Yu Z","year":"2020","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_76_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2014.07.005","article-title":"Correlation of cetuximab\u2010induced skin rash and outcomes of solid tumor patients treated with cetuximab: A systematic review and meta\u2010analysis","volume":"93","author":"Abdel\u2010Rahman O","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"e_1_2_12_77_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non\u2010small\u2010cell lung cancer patients treated with anti\u2010EGFR tyrosine kinase inhibitors: A literature\u2010based meta\u2010analysis of 24 trials","volume":"78","author":"Petrelli F","year":"2012","journal-title":"Lung Cancer"},{"key":"e_1_2_12_78_1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamadermatol.2017.0903","article-title":"Purpuric drug eruptions caused by epidermal growth factor receptor inhibitors for non\u2010small cell lung cancer: A Clinicopathologic study of 32 cases","volume":"153","author":"Cho YT","year":"2017","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_79_1","article-title":"Sweet syndrome as an adverse reaction to tyrosine kinase inhibitors: A review","volume":"34","author":"Yang JJ","year":"2021","journal-title":"Dermatol. Ther."},{"key":"e_1_2_12_80_1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/CAD.0000000000001494","article-title":"EGFR inhibitor\u2010induced folliculitis decalvans: A case series and management guidelines","volume":"34","author":"Nowaczyk J","year":"2023","journal-title":"Anti\u2010Cancer Drugs"},{"key":"e_1_2_12_81_1","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/ced\/llad282","article-title":"HLA\u2010C*15:02 and epidermal growth factor receptor inhibitor\u2010induced erosive pustular dermatosis of the scalp","volume":"48","author":"Zhang Y","year":"2023","journal-title":"Clin. Exp. Dermatol."},{"key":"e_1_2_12_82_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaip.2024.10.027","article-title":"Class I HLA alleles are associated with an increased risk of Osimertinib\u2010induced hypersensitivity","volume":"13","author":"Chen CB","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"e_1_2_12_83_1","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2017-0582","article-title":"Osimertinib: A novel dermatologic adverse event profile in patients with lung cancer","volume":"23","author":"Chu CY","year":"2018","journal-title":"Oncologist"},{"key":"e_1_2_12_84_1","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.2147\/DDDT.S168248","article-title":"A case report of toxic epidermal necrolysis associated with AZD\u20109291","volume":"12","author":"Wang J","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"e_1_2_12_85_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.lungcan.2019.01.009","article-title":"Mutation tracking of a patient with EGFR\u2010mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib","volume":"129","author":"Zheng X","year":"2019","journal-title":"Lung Cancer"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56080403"},{"key":"e_1_2_12_87_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.672233","article-title":"Case report: Stevens\u2010Johnson syndrome and hepatotoxicity induced by Osimertinib sequential to Pembrolizumab in a patient with EGFR\u2010mutated lung adenocarcinoma","volume":"12","author":"Gianni C","year":"2021","journal-title":"Front. Pharmacol."},{"key":"e_1_2_12_88_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.804212","article-title":"Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies","volume":"12","author":"Li Y","year":"2022","journal-title":"Front. Oncol."},{"key":"e_1_2_12_89_1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2016.02.015","article-title":"Afatinib\u2010associated Stevens\u2010Johnson syndrome in an EGFR\u2010mutated lung cancer patient","volume":"95","author":"Doesch J","year":"2016","journal-title":"Lung Cancer"},{"key":"e_1_2_12_90_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1684\/ejd.2016.2807","article-title":"Stevens\u2010Johnson syndrome\u2010like erosive dermatitis possibly related to afatinib","volume":"26","author":"Honda Y","year":"2016","journal-title":"Eur. J. Dermatol."},{"key":"e_1_2_12_91_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/ddg.13412","article-title":"Stevens\u2010Johnson syndrome\/toxic epidermal necrolysis overlap in a NSCLC patient treated with afatinib","volume":"16","author":"Nuhnen VP","year":"2018","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"e_1_2_12_92_1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/cup.12202","article-title":"Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors","volume":"40","author":"Brodell LA","year":"2013","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_93_1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/cup.12630","article-title":"Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients","volume":"43","author":"Bellini V","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_94_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF\u2010MEK\u2010ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah R","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"e_1_2_12_95_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061215"},{"key":"e_1_2_12_96_1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamadermatol.2015.1745","article-title":"Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma","volume":"151","author":"Carlos G","year":"2015","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_97_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cup.14145","article-title":"Diverse landscape of dermatologic toxicities from small\u2010molecule inhibitor cancer therapy","volume":"49","author":"Seervai RNH","year":"2022","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_98_1","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","article-title":"Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma","volume":"71","author":"Sanlorenzo M","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_99_1","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1457226","article-title":"Cutaneous adverse events associated with BRAF and MEK inhibitors: A systematic review and meta\u2010analysis","volume":"15","author":"Qian J","year":"2024","journal-title":"Front. Pharmacol."},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11121950"},{"key":"e_1_2_12_101_1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/ajd.12124","article-title":"Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib","volume":"55","author":"Anforth R","year":"2014","journal-title":"Australas. J. Dermatol."},{"key":"e_1_2_12_102_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/15569527.2018.1553180","article-title":"The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: A systematic review and meta\u2010analysis","volume":"38","author":"Chen P","year":"2019","journal-title":"Cutan. Ocul. Toxicol."},{"key":"e_1_2_12_103_1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1001\/jamadermatol.2016.2426","article-title":"Dermoscopic evaluation of melanocytic nevi changes with combined mitogen\u2010activated protein kinase pathway inhibitors therapy for melanoma","volume":"152","author":"Perier\u2010Muzet M","year":"2016","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_104_1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/DAD.0000000000000023","article-title":"Panniculitis in patients treated with BRAF inhibitors: A case series","volume":"36","author":"Choy B","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_105_1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2014.2512","article-title":"Clinical observation of panniculitis in two patients with BRAF\u2010mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor","volume":"25","author":"Galliker NA","year":"2015","journal-title":"Eur. J. Dermatol."},{"key":"e_1_2_12_106_1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1684\/ejd.2023.4467","article-title":"Panniculitis does not predict clinical response in patients with advanced melanoma under targeted therapy","volume":"33","author":"Piroth M","year":"2023","journal-title":"Eur. J. Dermatol."},{"key":"e_1_2_12_107_1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.13039","article-title":"Erythema nodosum\u2010like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature","volume":"29","author":"Mossner R","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_2_12_108_1","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.jaad.2020.07.044","article-title":"Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study","volume":"84","author":"Boull CL","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_109_1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jaad.2021.10.030","article-title":"BRAF inhibition and the spectrum of granulomatous reactions","volume":"87","author":"Pham JP","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_110_1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000439400","article-title":"Sarcoidosis in patients treated with Vemurafenib for metastatic melanoma: A paradoxical autoimmune activation","volume":"231","author":"Lheure C","year":"2015","journal-title":"Dermatology"},{"key":"e_1_2_12_111_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/CMR.0000000000000649","article-title":"Induced sarcoid\u2010like reactions in patients with metastatic melanoma treated with dabrafenib and trametinib: A monocentric retrospective study","volume":"30","author":"Huynh S","year":"2020","journal-title":"Melanoma Res."},{"key":"e_1_2_12_112_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CMR.0000000000000437","article-title":"Sarcoid\u2010like reactions in patients receiving modern melanoma treatment","volume":"28","author":"Dimitriou F","year":"2018","journal-title":"Melanoma Res."},{"key":"e_1_2_12_113_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1217179","article-title":"Case report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF\u2010mutant melanoma","volume":"13","author":"Dar N","year":"2023","journal-title":"Front. Oncol."},{"key":"e_1_2_12_114_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.humpath.2015.12.003","article-title":"BRAF inhibitor therapy\u2010associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression","volume":"50","author":"Mudaliar K","year":"2016","journal-title":"Hum. Pathol."},{"key":"e_1_2_12_115_1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.06.006","article-title":"Melanocytic nevi excised during B\u2010Raf proto\u2010oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients","volume":"73","author":"Mochel MC","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_116_1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/cup.70111","article-title":"PRAME\u2010positive eruptive melanocytic nevi in the setting of BRAF\u2010inhibitors","volume":"53","author":"Mackie MM","year":"2026","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_117_1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1001\/jamadermatol.2013.7919","article-title":"Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma","volume":"150","author":"Park JJ","year":"2014","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_118_1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/bjd.12279","article-title":"Novel cutaneous effects of combination chemotherapy with BRAF and MEK inhibitors: A report of two cases","volume":"169","author":"Green JS","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_119_1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/DAD.0000000000001276","article-title":"BRAF inhibitor\u2010associated granulomatous dermatitis: A report of 3 cases","volume":"41","author":"Hui Ong EL","year":"2019","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_120_1","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1097\/DAD.0000000000000230","article-title":"Panniculitis with necrotizing granulomata in a patient on BRAF inhibitor (Dabrafenib) therapy for metastatic melanoma","volume":"37","author":"Ramani NS","year":"2015","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_121_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer L","year":"2012","journal-title":"Arch. Dermatol."},{"key":"e_1_2_12_122_1","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): A multicentre, international, randomised, placebo\u2010controlled, parallel, double\u2010blind, phase 3 study","volume":"405","author":"Chen AP","year":"2025","journal-title":"Lancet"},{"key":"e_1_2_12_123_1","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform Neurofibromas","volume":"382","author":"Gross AM","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_124_1","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/13543784.2025.2599455","article-title":"Developments of MEK inhibitors as future cancer therapies: What have we learned from preclinical and clinical studies?","volume":"34","author":"Petrini I","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"e_1_2_12_125_1","article-title":"Mucocutaneous toxicities from MEK inhibitors: A scoping review of the literature","volume":"32","author":"Iriarte C","year":"2024","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_126_1","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1158\/1078-0432.CCR-09-1766","article-title":"Mitogen\u2010activated protein\/extracellular signal\u2010regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders","volume":"16","author":"Schad K","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_12_127_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaad.2023.06.052","article-title":"Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population","volume":"89","author":"Ahmed F","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_128_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamadermatol.2014.3207","article-title":"MEK inhibitor\u2010induced dusky erythema: Characteristic drug hypersensitivity manifestation in 3 patients","volume":"151","author":"Patel U","year":"2015","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_129_1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s10637-010-9567-3","article-title":"Dermatologic side effects associated with the MEK 1\/2 inhibitor selumetinib (AZD6244, ARRY\u2010142886)","volume":"29","author":"Balagula Y","year":"2011","journal-title":"Investig. New Drugs"},{"key":"e_1_2_12_130_1","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1634\/theoncologist.2016-0186","article-title":"Characterization and Management of Hedgehog Pathway Inhibitor\u2010Related Adverse Events in patients with advanced basal cell carcinoma","volume":"21","author":"Lacouture ME","year":"2016","journal-title":"Oncologist"},{"key":"e_1_2_12_131_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40257-023-00763-x","article-title":"Efficacy and safety of sonic hedgehog inhibitors in basal cell carcinomas: An updated systematic review and meta\u2010analysis (2009\u20102022)","volume":"24","author":"Nguyen A","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"e_1_2_12_132_1","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/bjd.15738","article-title":"From basal cell carcinoma morphogenesis to the alopecia induced by hedgehog inhibitors: Connecting the dots","volume":"177","author":"Dessinioti C","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_133_1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamadermatol.2015.4330","article-title":"Increased risk of cutaneous squamous cell carcinoma after Vismodegib therapy for basal cell carcinoma","volume":"152","author":"Mohan SV","year":"2016","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_134_1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jaad.2017.03.038","article-title":"Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib","volume":"77","author":"Bhutani T","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_135_1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jdv.12526","article-title":"Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib","volume":"29","author":"Saintes C","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_2_12_136_1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamadermatol.2014.583","article-title":"Two different scenarios of squamous cell carcinoma within advanced basal cell carcinomas: Cases illustrating the importance of serial biopsy during vismodegib usage","volume":"150","author":"Zhu GA","year":"2014","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_137_1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjd.13619","article-title":"Hair loss and hedgehog inhibitors: A class effect?","volume":"173","author":"Ferguson JS","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_138_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/DAD.0000000000001384","article-title":"Histologic changes during treatment with Vismodegib in locally advanced basal cell carcinoma: A series of 19 cases","volume":"41","author":"Bancalari B","year":"2019","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_139_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113676","article-title":"Multiple effects of CDK4\/6 inhibition in cancer: From cell cycle arrest to immunomodulation","volume":"170","author":"Bonelli M","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"e_1_2_12_140_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41573-026-01431-5","article-title":"The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond","volume":"25","author":"Knudsen ES","year":"2026","journal-title":"Nat. Rev. Drug Discov."},{"key":"e_1_2_12_141_1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00403-026-04599-3","article-title":"Cutaneous adverse events with CDK4\/6 inhibitors in breast cancer: A systematic review and meta\u2010analysis","volume":"318","author":"Liu R","year":"2026","journal-title":"Arch. Dermatol. Res."},{"key":"e_1_2_12_142_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15143658"},{"key":"e_1_2_12_143_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","article-title":"Skin toxicities with cyclin\u2010dependent kinase 4\/6 inhibitors in breast cancer: Signals from disproportionality analysis of the FDA adverse event reporting system","volume":"23","author":"Raschi E","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"e_1_2_12_144_1","article-title":"Retrospective cohort study of CDK4\/6\u2010inhibitor\u2010induced alopecia in breast cancer patients","volume":"31","author":"Minta A","year":"2023","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_145_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10549-020-05914-w","article-title":"Vitiligo\u2010like lesions in patients with advanced breast cancer treated with cycline\u2010dependent kinases 4 and 6 inhibitors","volume":"185","author":"Sollena P","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_12_146_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-023-07217-2","article-title":"Multi\u2010center retrospective review of vitiligo\u2010like lesions in breast cancer patients treated with cyclin\u2010dependent kinase 4 and 6 inhibitors","volume":"204","author":"Bang AS","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_12_147_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1184738","article-title":"Case report: Ribociclib\u2010induced phototoxicity presented as dyschromia with subsequent bullae formation","volume":"13","author":"Jhan JY","year":"2023","journal-title":"Front. Oncol."},{"key":"e_1_2_12_148_1","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin\u2010dependent kinase 4\/6 inhibitors: A systematic review","volume":"44","author":"Silvestri M","year":"2021","journal-title":"Drug Saf."},{"key":"e_1_2_12_149_1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cup.13673","article-title":"Subacute cutaneous lupus erythematosus with positive anti\u2010Ro antibodies following palbociclib and letrozole treatment: A case report and literature review","volume":"47","author":"Russell\u2010Goldman E","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_150_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","article-title":"Cutaneous toxicities occurring during palbociclib (CDK4\/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: A single\u2010centre experience","volume":"188","author":"Chawla S","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_12_151_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/ced\/llaf482","article-title":"Vitiligo\u2010like leucoderma following treatment with cyclin\u2010dependent kinase 4 and 6 inhibitors: Analysis of clinicopathological and immunohistochemical findings","volume":"51","author":"Engler Markowitz M","year":"2026","journal-title":"Clin. Exp. Dermatol."},{"key":"e_1_2_12_152_1","first-page":"587","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel P","year":"2021","journal-title":"Nat. Can."},{"key":"e_1_2_12_153_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano A","year":"2023","journal-title":"Mol. Cancer"},{"key":"e_1_2_12_154_1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K\u2010AKT and mTOR in advanced oestrogen receptor\u2010positive breast cancer","volume":"25","author":"Browne IM","year":"2024","journal-title":"Lancet Oncol."},{"key":"e_1_2_12_155_1","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-24-0967","article-title":"PI3K inhibitors in hematology: When one door closes","volume":"30","author":"Skanland SS","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_12_156_1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2022.4327","article-title":"Incidence of cutaneous adverse events with phosphoinositide 3\u2010kinase inhibitors as adjuvant therapy in patients with cancer: A systematic review and meta\u2010analysis","volume":"8","author":"Jfri A","year":"2022","journal-title":"JAMA Oncol."},{"key":"e_1_2_12_157_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201025\u20102764"},{"key":"e_1_2_12_158_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10549-020-05726-y","article-title":"Dermatologic adverse events related to the PI3Kalpha inhibitor alpelisib (BYL719) in patients with breast cancer","volume":"183","author":"Wang DG","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_12_159_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.36401\/JIPO-20-16","article-title":"Characterization of cutaneous adverse events associated with PI3K inhibitors in 11 patients","volume":"3","author":"Karri PV","year":"2020","journal-title":"J Immunother Precis Oncol."},{"key":"e_1_2_12_160_1","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3783","article-title":"Psoriasiform eruption secondary to PI3K\u2010delta inhibitor: Expanding the Spectrum of Psoriasiform paradoxical reactions?","volume":"101","author":"Pesque D","year":"2021","journal-title":"Acta Derm. Venereol."},{"key":"e_1_2_12_161_1","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jdcr.2018.03.005","article-title":"Psoriasiform eruptions secondary to phosphoinositide 3\u2010kinase inhibition","volume":"5","author":"Dewan AK","year":"2019","journal-title":"JAAD Case Rep."},{"key":"e_1_2_12_162_1","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/ced.13608","article-title":"Pityriasis rubra pilaris\u2010like erythroderma secondary to phosphoinositide 3\u2010kinase inhibition","volume":"43","author":"Dewan AK","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"key":"e_1_2_12_163_1","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2024.2387317","article-title":"Post\u2010marketing safety concern of PI3K inhibitors in the cancer therapies: An 8\u2010year disproportionality analysis from the FDA adverse event reporting system","volume":"24","author":"Lin X","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"e_1_2_12_164_1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamaoncol.2019.0034","article-title":"Safety, tolerability, and Management of Toxic Effects of phosphatidylinositol 3\u2010kinase inhibitor treatment in patients with cancer: A review","volume":"5","author":"Esposito A","year":"2019","journal-title":"JAMA Oncol."},{"key":"e_1_2_12_165_1","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.4049\/jimmunol.178.6.3358","article-title":"Cutting edge: Chemokine receptor CCR4 is necessary for antigen\u2010driven cutaneous accumulation of CD4 T\u00a0cells under physiological conditions","volume":"178","author":"Campbell JJ","year":"2007","journal-title":"J. Immunol."},{"key":"e_1_2_12_166_1","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/eji.202049043","article-title":"CCR4 in cutaneous T\u2010cell lymphoma: Therapeutic targeting of a pathogenic driver","volume":"51","author":"Nicolay JP","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"e_1_2_12_167_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjd.20708","article-title":"Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T\u2010cell lymphoma: A retrospective single\u2010centre case series","volume":"186","author":"Trum NA","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_168_1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of Mogamulizumab\u2010associated rash during treatment of mycosis Fungoides or Sezary syndrome","volume":"157","author":"Hirotsu KE","year":"2021","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_169_1","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1111\/jdv.19801","article-title":"Clinicopathological definition, management and prognostic value of mogamulizumab\u2010associated rash and other cutaneous events: A systematic review","volume":"38","author":"Avallone G","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_2_12_170_1","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic characterization of Mogamulizumab\u2010associated rash","volume":"44","author":"Wang JY","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"e_1_2_12_171_1","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ddg.15773","article-title":"Novel and recurrent histopathologic patterns of mogamulizumab\u2010associated rash: Diagnostic implications and insights for accurate diagnosis","volume":"23","author":"Mitteldorf C","year":"2025","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"e_1_2_12_172_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1243459","article-title":"Utility of T\u2010cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events","volume":"10","author":"Bhatti S","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"e_1_2_12_173_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR\u2010ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman LS","year":"2004","journal-title":"Leukemia"},{"key":"e_1_2_12_174_1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ajh.26695","article-title":"Tyrosine kinase inhibitors dosing for chronic phase chronic myeloid leukemia: The case for starting low with dasatinib (50 mg\/day) and ponatinib (15 mg\/day)","volume":"97","author":"Tefferi A","year":"2022","journal-title":"Am. J. Hematol."},{"key":"e_1_2_12_175_1","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/0284186X.2023.2263152","article-title":"Comparison of cutaneous adverse events between second\u2010generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: A systematic review and meta\u2010analysis","volume":"62","author":"Cha SH","year":"2023","journal-title":"Acta Oncol."},{"key":"e_1_2_12_176_1","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2217\/fon-2022-1008","article-title":"Rash with different types of BCR\u2010ABL inhibitors in chronic myelogenous leukemia: A systematic review and meta\u2010analysis","volume":"19","author":"Li S","year":"2023","journal-title":"Future Oncol."},{"key":"e_1_2_12_177_1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/DAD.0000000000003125","article-title":"Histopathologic and clinical characteristics of cutaneous toxicities of tyrosine kinase inhibitors: Insights into pathologic mechanisms from a retrospective cohort","volume":"47","author":"Nykaza I","year":"2025","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_178_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000437383","article-title":"Unique cutaneous reaction to second\u2010 and third\u2010generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"232","author":"Patel AB","year":"2016","journal-title":"Dermatology"},{"key":"e_1_2_12_179_1","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/ejh.12052","article-title":"Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: Meta\u2010analysis and clinical characterization","volume":"90","author":"Drucker AM","year":"2013","journal-title":"Eur. J. Haematol."},{"key":"e_1_2_12_180_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/pde.15505","article-title":"Skin reactions to tyrosine kinase inhibitors in pediatric patients with chronic myeloid leukemia","volume":"41","author":"Toker M","year":"2024","journal-title":"Pediatr. Dermatol."},{"key":"e_1_2_12_181_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/DAD.0000000000002344","article-title":"Ponatinib\u2010associated cutaneous eruptions\u2010a case series and review of Clinicopathologic findings","volume":"45","author":"Weber I","year":"2023","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_182_1","first-page":"e268","article-title":"Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib","volume":"55","author":"Lee WJ","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"e_1_2_12_183_1","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T\u00a0cells and T\u2010cell therapies for cancer: A translational science review","volume":"332","author":"Brudno JN","year":"2024","journal-title":"JAMA"},{"key":"e_1_2_12_184_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jama.2025.21721","article-title":"Advancing CAR T\u2010cell therapy: Evidence\u2010based trial Design for Chimeric Antigen Receptor T\u2010cell therapy in oncology","volume":"335","author":"Mahat U","year":"2026","journal-title":"JAMA"},{"key":"e_1_2_12_185_1","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/bloodadvances.2020004038","article-title":"Absolute lymphocyte count proliferation kinetics after CAR T\u2010cell infusion impact response and relapse","volume":"5","author":"Faude S","year":"2021","journal-title":"Blood Adv."},{"key":"e_1_2_12_186_1","first-page":"1035","article-title":"Dermatologic adverse events associated with chimeric antigen receptor T\u2010cell therapy: A pharmacovigilance analysis of the FDA reporting system","volume":"30","author":"Storgard R","year":"2024","journal-title":"Transplant Cell Ther."},{"key":"e_1_2_12_187_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa2505478","article-title":"Universal Base\u2010edited CAR7 T\u00a0cells for T\u2010cell acute lymphoblastic leukemia","volume":"394","author":"Chiesa R","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_188_1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","article-title":"Base\u2010edited CAR7 T\u00a0cells for relapsed T\u2010cell acute lymphoblastic leukemia","volume":"389","author":"Chiesa R","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_189_1","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti\u2010CD30 CAR\u2010T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos CA","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_12_190_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-13400-5","article-title":"Safety and efficacy of anti\u2010CD30 CAR\u2010T cell therapy in relapsed\/refractory classic Hodgkin lymphoma: A systematic review and meta\u2010analysis","volume":"25","author":"Meng F","year":"2025","journal-title":"BMC Cancer"},{"key":"e_1_2_12_191_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1644818","article-title":"Case report: Rare adverse events following CAR\u2010T therapy in patients with relapsed\/refractory diffuse large B\u2010cell lymphoma","volume":"15","author":"Shah Z","year":"2025","journal-title":"Front. Oncol."},{"key":"e_1_2_12_192_1","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamadermatol.2020.0636","article-title":"Bullous and Exanthematous lesions associated with chimeric antigen receptor T\u2010cell therapy in a patient with diffuse large B\u2010cell lymphoma","volume":"156","author":"Hu Y","year":"2020","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_193_1","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1111\/jdv.18892","article-title":"Cutaneous toxicity of CAR T\u2010cell therapy: Case report of a bullous life\u2010threatening reaction","volume":"37","author":"Fiorillo G","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_2_12_194_1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cup.14687","article-title":"Toxic epidermal necrolysis\u2010like cutaneous toxicity following chimeric antigen receptor T\u2010cell therapy in recurrent large B\u2010cell lymphoma","volume":"51","author":"Bhullar PK","year":"2024","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_195_1","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell\u2010associated toxicity syndrome in CAR T\u2010cell treated patients with autoimmune disease: An observational study","volume":"7","author":"Hagen M","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"e_1_2_12_196_1","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1182\/blood.2025030059","article-title":"Immune\u2010mediated side effects of cancer immunotherapies","volume":"147","author":"Braun LM","year":"2026","journal-title":"Blood"},{"key":"e_1_2_12_197_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61683","article-title":"Late adverse events after chimeric antigen receptor T\u2010cell therapy for patients with aggressive B\u2010cell non\u2010Hodgkin lymphoma","volume":"8","author":"Camacho\u2010Arteaga L","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"e_1_2_12_198_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti\u2010EGFR chimeric antigen receptor\u2010modified T\u00a0cells in metastatic pancreatic carcinoma: A phase I clinical trial","volume":"22","author":"Liu Y","year":"2020","journal-title":"Cytotherapy"},{"key":"e_1_2_12_199_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-016-0378-7","article-title":"Cocktail treatment with EGFR\u2010specific and CD133\u2010specific chimeric antigen receptor\u2010modified T\u00a0cells in a patient with advanced cholangiocarcinoma","volume":"10","author":"Feng KC","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"e_1_2_12_200_1","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","article-title":"GPRC5D CAR T\u00a0cells (OriCAR\u2010017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first\u2010in\u2010human, single\u2010centre, single\u2010arm, phase 1 trial","volume":"10","author":"Zhang M","year":"2023","journal-title":"Lancet Haematol."},{"key":"e_1_2_12_201_1","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41434-025-00586-x","article-title":"Secondary malignancy of T\u2010cell origin after CAR T\u2010cell therapy: EMA's conclusions from the evaluation of 38 suspected cases","volume":"33","author":"Berg P","year":"2025","journal-title":"Gene Ther."},{"key":"e_1_2_12_202_1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41571-026-01147-w","article-title":"Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post\u2010CAR T\u00a0cell therapy lymphoproliferative disorders","volume":"23","author":"Ali A","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"e_1_2_12_203_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1056\/NEJMc2504588","article-title":"Targeted therapy of CAR+ T\u2010cell lymphoma after anti\u2010BCMA CAR T\u2010cell therapy","volume":"393","author":"Aleman A","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_204_1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa2309728","article-title":"CAR+ T\u2010cell lymphoma after Cilta\u2010cel therapy for relapsed or refractory myeloma","volume":"392","author":"Harrison SJ","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_205_1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2016.06.062","article-title":"Evaluating the skin in patients undergoing chimeric antigen receptor modified T\u2010cell therapy","volume":"75","author":"Rubin CB","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_206_1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","journal-title":"Curr. Oncol."},{"key":"e_1_2_12_207_1","doi-asserted-by":"crossref","DOI":"10.1007\/s44272-025-00043-1","article-title":"Multi\u2010disciplinary expert consensus on cutaneous adverse events caused by immune checkpoint inhibitors (2025)","volume":"4","author":"Sun Y","year":"2025","journal-title":"Clin. Cancer Bull."},{"key":"e_1_2_12_208_1","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2012.12.963","article-title":"The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta\u2010analysis","volume":"69","author":"Minkis K","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_209_1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/2326-6066.CIR-14-0134","article-title":"Lichenoid dermatitis in three patients with metastatic melanoma treated with anti\u2010PD\u20101 therapy","volume":"3","author":"Joseph RW","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"e_1_2_12_210_1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry JL","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_211_1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/17425255.2016.1120287","article-title":"New toxicity profile for novel immunotherapy agents: Focus on immune\u2010checkpoint inhibitors","volume":"12","author":"Ciccarese C","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"e_1_2_12_212_1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/jamadermatol.2018.1912","article-title":"Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy","volume":"154","author":"Wang LL","year":"2018","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_213_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24286-3","article-title":"Cutaneous adverse events in patients treated with PD\u20101\/PD\u2010L1 checkpoint inhibitors and their association with survival: A systematic review and meta\u2010analysis","volume":"12","author":"Zhao F","year":"2022","journal-title":"Sci. Rep."},{"key":"e_1_2_12_214_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo with Tumor Response in patients with metastatic melanoma treated with Pembrolizumab","volume":"152","author":"Hua C","year":"2016","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_215_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/cup.13013","article-title":"PD\u20101 inhibitor\u2010associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation\u2010report of 4 cases","volume":"44","author":"Chou S","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_216_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdin.2021.12.003","article-title":"Immune checkpoint inhibitor induced lichenoid reactions: A systematic review of characteristics and treatment outcomes","volume":"7","author":"Abduelmula A","year":"2022","journal-title":"JAAD Int."},{"key":"e_1_2_12_217_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: A detailed examination of the Clinicopathologic features","volume":"39","author":"Tetzlaff MT","year":"2017","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_218_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/DAD.0000000000000587","article-title":"Histologic assessment of lichenoid dermatitis observed in patients with advanced malignancies on Antiprogramed cell Death\u20101 (anti\u2010PD\u20101) therapy with or without Ipilimumab","volume":"39","author":"Chou S","year":"2017","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_219_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cup.12666","article-title":"Immunohistochemical analysis of lichenoid reactions in patients treated with anti\u2010PD\u2010L1 and anti\u2010PD\u20101 therapy","volume":"43","author":"Schaberg KB","year":"2016","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_220_1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid Mucocutaneous eruptions due to anti\u2010programmed cell death 1 and anti\u2010programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi VJ","year":"2016","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_221_1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD\u20101\/PD\u2010L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case\u2010control study","volume":"79","author":"Min Lee CK","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_222_1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy","volume":"19","author":"Sibaud V","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"e_1_2_12_223_1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single\u2010institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman E","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_224_1","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/PAS.0000000000000900","article-title":"Cutaneous eruptions in patients receiving immune checkpoint blockade: Clinicopathologic analysis of the nonlichenoid histologic pattern","volume":"41","author":"Kaunitz GJ","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"e_1_2_12_225_1","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jaad.2025.08.008","article-title":"Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors","volume":"93","author":"Azin M","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_226_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo P","year":"2021","journal-title":"Dermatol. Ther."},{"key":"e_1_2_12_227_1","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint\u2010mediated psoriasis: A multicenter European study of 115 patients from the European network for cutaneous adverse event to oncologic drugs (ENCADO) group","volume":"84","author":"Nikolaou V","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_228_1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jaad.2022.02.030","article-title":"Treatment of immune checkpoint inhibitor\u2010mediated psoriasis: A systematic review","volume":"87","author":"Said JT","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_229_1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1001\/jamadermatol.2015.5210","article-title":"Inverse Psoriasiform eruption during Pembrolizumab therapy for metastatic melanoma","volume":"152","author":"Totonchy MB","year":"2016","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_230_1","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s13555-024-01198-w","article-title":"Psoriasis in the era of targeted cancer therapeutics: A systematic review on De novo and pre\u2010existing psoriasis in oncologic patients treated with emerging anti\u2010neoplastic agents","volume":"14","author":"Madan V","year":"2024","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"e_1_2_12_231_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jdcr.2024.09.027","article-title":"IL\u201023 inhibitor treatment of immune checkpoint inhibitor\u2010associated psoriasis: Case series and review of literature","volume":"56","author":"Bourand N","year":"2025","journal-title":"JAAD Case Rep."},{"key":"e_1_2_12_232_1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","article-title":"Management of Cutaneous Immune\u2010Related Adverse Events in patients with cancer treated with immune checkpoint inhibitors: A systematic review","volume":"8","author":"Nadelmann ER","year":"2022","journal-title":"JAMA Oncol."},{"key":"e_1_2_12_233_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.det.2024.02.012","article-title":"Immune checkpoint inhibitor\u2010induced psoriasis: Diagnosis, management, and a review of cases","volume":"42","author":"Pach JJ","year":"2024","journal-title":"Dermatol. Clin."},{"key":"e_1_2_12_234_1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/cup.14406","article-title":"Coexistence of psoriasiform stratum corneum and underlying lichenoid features in skin biopsies of cutaneous reactions to anti\u2010PD1","volume":"50","author":"Butron\u2010Bris B","year":"2023","journal-title":"J. Cutan. Pathol."},{"issue":"16","key":"e_1_2_12_235_1","article-title":"Histopathological distinction between ICI\u2010induced psoriasis vulgaris and psoriasiform dermatitis in patients with immune\u2010related cutaneous adverse events (irDAEs): A multicenter prospective observational study","volume":"44","author":"Nazarova VV","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_12_236_1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jdrv.2025.11.002","article-title":"Immune checkpoint inhibitor\u2010induced bullous pemphigoid: A clinical review","volume":"7","author":"Lambert RA","year":"2026","journal-title":"JAAD Reviews."},{"key":"e_1_2_12_237_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020323"},{"key":"e_1_2_12_238_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab","volume":"25","author":"Carlos G","year":"2015","journal-title":"Melanoma Res."},{"key":"e_1_2_12_239_1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD\u20101 and PD\u2010L1","volume":"4","author":"Naidoo J","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"e_1_2_12_240_1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of Bullous Pemphigoid with Immune Checkpoint Inhibitor Therapy in patients with cancer: A systematic review","volume":"158","author":"Asdourian MS","year":"2022","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_241_1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/DAD.0000000000002139","article-title":"Lichen planus Pemphigoides associated with PD\u20101 and PD\u2010L1 inhibitors: A case series and review of the literature","volume":"44","author":"Boyle MM","year":"2022","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_242_1","first-page":"e90","article-title":"Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab","volume":"46","author":"Ito M","year":"2019","journal-title":"J. Dermatol."},{"key":"e_1_2_12_243_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00262","article-title":"Recurrence of pemphigus vulgaris under Nivolumab therapy","volume":"6","author":"Krammer S","year":"2019","journal-title":"Front. Med. (Lausanne)."},{"key":"e_1_2_12_244_1","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti\u2010PD\u20101 and anti\u2010PD\u2010L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel J","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_245_1","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1111\/bjd.21653","article-title":"Atezolizumab\u2010induced linear IgA bullous dermatosis","volume":"187","author":"Aguilar\u2010Duran S","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_246_1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.jaad.2022.10.020","article-title":"Immune checkpoint inhibitor\u2010induced bullous pemphigoid quandaries","volume":"87","author":"Heymann WR","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_247_1","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy\u2010induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur D","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_248_1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous pemphigoid after anti\u2013programmed death\u20101 therapy: A retrospective case\u2010control study evaluating impact on tumor response and survival outcomes","volume":"87","author":"Nelson CA","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_249_1","doi-asserted-by":"crossref","DOI":"10.1159\/000552077","article-title":"Comparative clinical and histological analysis of bullous pemphigoid: Immunotherapy\u2010associated vs. spontaneous onset cases","author":"Gwerder T","year":"2026","journal-title":"Dermatology"},{"key":"e_1_2_12_250_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1095694","article-title":"Analysis of the clinical characteristics of pembrolizumab\u2010induced bullous pemphigoid","volume":"13","author":"Wang J","year":"2023","journal-title":"Front. Oncol."},{"key":"e_1_2_12_251_1","doi-asserted-by":"crossref","DOI":"10.1111\/exd.70241","article-title":"Immune checkpoint inhibitor\u2010related bullous pemphigoid: Distinct clinical and immunological profiles","volume":"35","author":"Zou M","year":"2026","journal-title":"Exp. Dermatol."},{"key":"e_1_2_12_252_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/cup.13687","article-title":"Neutrophil\u2010predominant bullous pemphigoid induced by checkpoint inhibitors: A case series","volume":"47","author":"Morris LM","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_253_1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized bullous mucocutaneous eruption mimicking Stevens\u2010Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series","volume":"83","author":"Molina GE","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_254_1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejca.2020.12.018","article-title":"Immune checkpoint inhibitor\u2010related epidermal necrolysis: A rare condition with poor prognosis","volume":"145","author":"He C","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"e_1_2_12_255_1","doi-asserted-by":"crossref","DOI":"10.1007\/s00403-024-03061-6","article-title":"Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: A review of 98 cases","volume":"316","author":"Bray ER","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"e_1_2_12_256_1","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/ijd.16572","article-title":"Successful rechallenge with pembrolizumab after case of progressive immunotherapy\u2010related mucocutaneous eruption (PIRME), a Stevens\u2010Johnson syndrome\u2010like reaction","volume":"62","author":"Shi CR","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"e_1_2_12_257_1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/DAD.0000000000003083","article-title":"Progressive immunotherapy\u2010related Mucocutaneous eruption: A mimicker of SJS\u2010TEN","volume":"47","author":"Sangani KA","year":"2025","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_258_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2025\u20100294\u2010RA"},{"key":"e_1_2_12_259_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54180-7","article-title":"Immune checkpoint inhibitor\u2010induced severe epidermal necrolysis mediated by macrophage\u2010derived CXCL10 and abated by TNF blockade","volume":"15","author":"Chen CB","year":"2024","journal-title":"Nat. Commun."},{"key":"e_1_2_12_260_1","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens\u2010Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung WH","year":"2008","journal-title":"Nat. Med."},{"key":"e_1_2_12_261_1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3899\/jrheum.2025-0108","article-title":"Necrotizing and nonnecrotizing granulomatous reactions in patients with cancer treated with immune checkpoint inhibitors: A systematic literature review","volume":"52","author":"Wang EY","year":"2025","journal-title":"J. Rheumatol."},{"key":"e_1_2_12_262_1","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaad.2018.07.051","article-title":"Immune checkpoint inhibitors and the development of granulomatous reactions","volume":"81","author":"Cornejo CM","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_263_1","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s10147-019-01490-2","article-title":"Immune checkpoint inhibitor\u2010induced sarcoidosis\u2010like granulomas","volume":"24","author":"Rambhia PH","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"e_1_2_12_264_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2017.06.014","article-title":"Diffuse granulomatous panniculitis associated with anti PD\u20101 antibody therapy","volume":"4","author":"Jiang B","year":"2018","journal-title":"JAAD Case Rep."},{"key":"e_1_2_12_265_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.humpath.2019.07.001","article-title":"Immune checkpoint blocker\u2010related sarcoid\u2010like granulomatous inflammation: A rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma","volume":"91","author":"Rodriguez EF","year":"2019","journal-title":"Hum. Pathol."},{"key":"e_1_2_12_266_1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40425-018-0323-0","article-title":"Granulomatous\/sarcoid\u2010like lesions associated with checkpoint inhibitors: A marker of therapy response in a subset of melanoma patients","volume":"6","author":"Tetzlaff MT","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"e_1_2_12_267_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1432927","article-title":"Case report: The immune architecture of immunotherapy\u2010induced cutaneous sarcoidosis resembles peritumoral inflammation","volume":"16","author":"Wang CJ","year":"2025","journal-title":"Front. Immunol."},{"key":"e_1_2_12_268_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/cup.13569","article-title":"Granulomatous\/sarcoid\u2010like reactions in the setting of programmed cell death\u20101 inhibition: A potential mimic of disease recurrence","volume":"47","author":"Hiraki T","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_269_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/DAD.0000000000001509","article-title":"Histopathological features of subcutaneous sarcoidosis","volume":"42","author":"Marcoval J","year":"2020","journal-title":"Am. J. Dermatopathol."},{"key":"e_1_2_12_270_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/cup.13150","article-title":"Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern","volume":"45","author":"Trinidad C","year":"2018","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_271_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cup.13562","article-title":"Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD\u20101 inhibitor therapy for metastatic melanoma","volume":"47","author":"Singh P","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_272_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/cup.13133","article-title":"Granulomatous and lichenoid dermatitis after IgG4 anti\u2010PD\u20101 monoclonal antibody therapy for advanced cancer","volume":"45","author":"Diaz\u2010Perez JA","year":"2018","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_273_1","first-page":"e834","article-title":"Immune checkpoint inhibitor\u2010associated panniculitis: Clinicopathological features and cytokine profiles","volume":"36","author":"Hung YT","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_2_12_274_1","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1001\/jamadermatol.2025.0359","article-title":"Immune checkpoint inhibitor\u2010induced lipodystrophy","volume":"161","author":"Riganti J","year":"2025","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_275_1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1710985","article-title":"Case report: Generalized lipodystrophy following immune\u2010checkpoint inhibitor therapy","volume":"16","author":"Lee AH","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"e_1_2_12_276_1","first-page":"E22","article-title":"Pembrolizumab\u2010induced lobular panniculitis in the setting of metastatic melanoma","volume":"105","author":"Peterman CM","year":"2020","journal-title":"Cutis"},{"key":"e_1_2_12_277_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jdcr.2021.05.002","article-title":"Erythema nodosum\u2010like panniculitis associated with immune checkpoint inhibitor therapy: Two cases reporting a rare cutaneous adverse event","volume":"13","author":"Pach J","year":"2021","journal-title":"JAAD Case Rep."},{"key":"e_1_2_12_278_1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/cup.13044","article-title":"Erythema nodosum\u2010like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy\u2010report of 2 patients","volume":"44","author":"Tetzlaff MT","year":"2017","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_279_1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad N","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"e_1_2_12_280_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jamadermatol.2024.0390","article-title":"Keratoacanthoma and cutaneous squamous cell carcinoma with PD\u20101 and PD\u2010L1 inhibitor use","volume":"160","author":"Aggarwal P","year":"2024","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_281_1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jdcr.2020.02.024","article-title":"Formation of eruptive cutaneous squamous cell carcinomas after programmed cell death protein\u20101 blockade","volume":"6","author":"Marsh RL","year":"2020","journal-title":"JAAD Case Rep."},{"key":"e_1_2_12_282_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4103\/ijdvl.IJDVL_147_18","article-title":"Eruptive squamous cell carcinomas associated with programmed cell death protein\u20101 inhibitor therapy","volume":"85","author":"Lee J","year":"2019","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"e_1_2_12_283_1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jdcr.2019.01.025","article-title":"Transient eruptive keratoacanthomas associated with nivolumab","volume":"5","author":"Antonov NK","year":"2019","journal-title":"JAAD Case Rep."},{"key":"e_1_2_12_284_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cup.13587","article-title":"Pembrolizumab\u2010induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus","volume":"47","author":"Coscarart A","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_285_1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive Keratoacanthomas associated with Pembrolizumab therapy","volume":"153","author":"Freites\u2010Martinez A","year":"2017","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_286_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15472","article-title":"Multiple eruptive squamoproliferative lesions during anti\u2010PD1 immunotherapy for metastatic melanoma: Pathogenesis, immunohistochemical analysis and treatment","volume":"35","author":"Star P","year":"2022","journal-title":"Dermatol. Ther."},{"key":"e_1_2_12_287_1","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cup.13739","article-title":"Hypertrophic lichenoid dermatitis immune\u2010related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma","volume":"47","author":"Marques\u2010Piubelli ML","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_288_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1634\/theoncologist.2019-0796","article-title":"Hypertrophic lichen planus with histological features of squamous cell carcinoma associated with immune checkpoint blockade therapy","volume":"25","author":"Ameri AH","year":"2020","journal-title":"Oncologist"},{"key":"e_1_2_12_289_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13074","article-title":"Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review","volume":"32","author":"Ravi V","year":"2019","journal-title":"Dermatol. Ther."},{"key":"e_1_2_12_290_1","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/j.jaad.2014.06.042","article-title":"Ipilimumab\u2010associated sweet syndrome in a melanoma patient","volume":"71","author":"Gormley R","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_291_1","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.jaad.2013.11.022","article-title":"Ipilimumab\u2010associated sweet syndrome in a patient with high\u2010risk melanoma","volume":"70","author":"Kyllo RL","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_292_1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CMR.0000000000000017","article-title":"Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy","volume":"23","author":"Pintova S","year":"2013","journal-title":"Melanoma Res."},{"key":"e_1_2_12_293_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1684\/ejd.2014.2297","article-title":"Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma \u2010 simultaneous occurrence of pyoderma gangrenosum and colitis","volume":"24","author":"Rudolph BM","year":"2014","journal-title":"Eur. J. Dermatol."},{"key":"e_1_2_12_294_1","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis SR","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_2_12_295_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/CMR.0000000000000261","article-title":"Ipilimumab\u2010induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma","volume":"26","author":"Hwang SJ","year":"2016","journal-title":"Melanoma Res."},{"key":"e_1_2_12_296_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40801-023-00399-7","article-title":"Immune checkpoint inhibitors and scleroderma: Data from the European pharmacovigilance database","volume":"11","author":"Nicoletti MM","year":"2024","journal-title":"Drugs Real World Outcomes."},{"key":"e_1_2_12_297_1","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jdcr.2025.12.027","article-title":"Immune checkpoint inhibitor\u2010associated scleroderma refractory to corticosteroids: Clinical improvement with intravenous immune globulin and dupilumab","volume":"70","author":"Abul\u2010Enin DG","year":"2026","journal-title":"JAAD Case Rep."},{"key":"e_1_2_12_298_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020259"},{"key":"e_1_2_12_299_1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by Pembrolizumab: A case series","volume":"92","author":"Barbosa NS","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"e_1_2_12_300_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma\u2010like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks BJ","year":"2018","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_301_1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug\u2010associated dermatomyositis following ipilimumab therapy: A novel immune\u2010mediated adverse event associated with cytotoxic T\u2010lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali S","year":"2015","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_302_1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jamadermatol.2023.5418","article-title":"Causes and clinical presentation of drug\u2010induced Dermatomyositis: A systematic review","volume":"160","author":"Caravan S","year":"2024","journal-title":"JAMA Dermatol."},{"key":"e_1_2_12_303_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103375","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","volume":"22","author":"Guerra NL","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"e_1_2_12_304_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: A case report and review of the literature","volume":"30","author":"Kosche C","year":"2020","journal-title":"Melanoma Res."},{"key":"e_1_2_12_305_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/CMR.0000000000000587","article-title":"Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: A report of three cases","volume":"29","author":"Blakeway EA","year":"2019","journal-title":"Melanoma Res."},{"key":"e_1_2_12_306_1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CMR.0000000000000536","article-title":"Subacute cutaneous lupus erythematosus induced by nivolumab: Two case reports and a literature review","volume":"29","author":"Zitouni NB","year":"2019","journal-title":"Melanoma Res."},{"key":"e_1_2_12_307_1","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.40801","article-title":"Novel onset of cutaneous lupus erythematosus induced by Pembrolizumab","volume":"104","author":"Pogorelov D","year":"2024","journal-title":"Acta Derm. Venereol."},{"key":"e_1_2_12_308_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.rdc.2024.01.007","article-title":"De novo connective tissue disorders as immune\u2010related adverse events","volume":"50","author":"Cho LK","year":"2024","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"e_1_2_12_309_1","doi-asserted-by":"crossref","DOI":"10.1007\/s00403-024-03484-1","article-title":"Clinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD\u20101\/PD\u2010L1 inhibitors","volume":"316","author":"Wu Z","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"e_1_2_12_310_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cup.13059","article-title":"Lupus\u2010like cutaneous reaction following pembrolizumab: An immune\u2010related adverse event associated with anti\u2010PD\u20101 therapy","volume":"45","author":"Shao K","year":"2018","journal-title":"J. Cutan. Pathol."},{"key":"e_1_2_12_311_1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus\u2010like eruptions in the setting of programmed death\u20101 or programmed death ligand\u20101 inhibitor therapy: Clinicopathological correlation","volume":"46","author":"Bui AN","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"e_1_2_12_312_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152440","article-title":"A scoping review of vasculitis as an immune\u2010related adverse event from checkpoint inhibitor therapy of cancer: Unraveling the complexities at the intersection of immunology and vascular pathology","volume":"66","author":"Lee CM","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"e_1_2_12_313_1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CJI.0000000000000352","article-title":"Checkpoint inhibitor\u2010associated cutaneous small vessel Vasculitis: A review of the literature","volume":"44","author":"Ho B","year":"2021","journal-title":"J. Immunother."},{"key":"e_1_2_12_314_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1537825","article-title":"Case report: Acral vasculitis induced by immune checkpoint inhibitors: A case series and literature review","volume":"15","author":"Rivet V","year":"2025","journal-title":"Front. Oncol."},{"key":"e_1_2_12_315_1","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1007\/s00296-024-05709-y","article-title":"Digital ischemia: A rare immune\u2010related adverse event of immune checkpoint inhibitors\u2010case report and review of the literature","volume":"44","author":"Yerolatsite M","year":"2024","journal-title":"Rheumatol. Int."},{"key":"e_1_2_12_316_1","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","volume":"6","author":"Padda A","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"e_1_2_12_317_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000457","article-title":"Pembrolizumab\u2010Induced Acral Vasculitis","volume":"46","author":"Yohannan B","year":"2023","journal-title":"J. Immunother."}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70286","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/his.70286","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.70286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:56:08Z","timestamp":1790243768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/his.70286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":316,"alternative-id":["10.1111\/his.70286"],"URL":"https:\/\/doi.org\/10.1111\/his.70286","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"2026-09-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"his.70286"}}